PDS Biotechnology Corp Proceeds from Issuance of Warrants
PDS Biotechnology Corp (PDSB) reported Proceeds from Issuance of Warrants of $1.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfWarrants · last filed 2026-08-13
- PDS Biotechnology Corp proceeds from issuance of warrants for the quarter ending 2026-06-30 was $1.05M.
- PDS Biotechnology Corp proceeds from issuance of warrants for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- PDS Biotechnology Corp proceeds from issuance of warrants for the quarter ending 2025-12-31 was $3.17M.
- PDS Biotechnology Corp proceeds from issuance of warrants for the quarter ending 2025-09-30 was $0.00.
- PDS Biotechnology Corp proceeds from issuance of warrants for fiscal 2025 was $5.32M.
- PDS Biotechnology Corp proceeds from issuance of warrants for fiscal 2024 was $0.00.
| Period end | Proceeds from Issuance of Warrants 3 month | Proceeds from Issuance of Warrants 6 month | Proceeds from Issuance of Warrants 9 month | Proceeds from Issuance of Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.05M 10-Q · filed 2026-08-13 | $4.22M derived: sum of 3 quarters · filed 2026-08-13 | $4.22M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | $3.17M derived: sum of 2 quarters · filed 2026-05-14 | $3.17M derived: sum of 3 quarters · filed 2026-05-14 | $3.17M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.17M derived: sum of 2 quarters · filed 2026-03-30 | $3.17M derived: sum of 3 quarters · filed 2026-08-13 | $5.32M 10-K · filed 2026-03-30 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $2.15M 10-Q · filed 2025-11-13 | $2.15M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.15M 10-Q · filed 2026-08-13 | $2.15M derived: sum of 3 quarters · filed 2026-08-13 | $2.15M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.15M 10-Q · filed 2026-05-14 | $2.15M derived: sum of 2 quarters · filed 2026-05-14 | $2.15M derived: sum of 3 quarters · filed 2026-05-14 | $2.15M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $0.00 derived: sum of 3 quarters · filed 2026-03-30 | $0.00 10-K · filed 2026-03-30 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |